Effect of cabergoline on metabolism in prolactinomas

Neuroendocrinology

Volumn 98, Issue 4, 2014, Pages 299-310

  Auriemma, Renata S ^a   Granieri, Luciana ^a   Galdiero, Mariano ^a   Simeoli, Chiara ^a   Perone, Ylenia ^a   Vitale, Pasquale ^a   Pivonello, Claudia ^a   Negri, Mariarosaria ^a   Mannarino, Teresa ^a   Giordano, Carla ^b   Gasperi, Maurizio ^c   Colao, Annamaria ^a   Pivonello, Rosario ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Cabergoline; Hyperprolactinemia; Insulin resistance; Metabolic parameters; Metabolic syndrome; Metabolism; Pituitary tumors; Prolactin; Visceral adiposity index

Indexed keywords

CABERGOLINE; INSULIN; PROLACTIN; ANTINEOPLASTIC AGENT; ERGOLINE DERIVATIVE; LIPID;

ADENOMA; ADULT; ARTICLE; DIET RESTRICTION; DISEASE CONTROL; FEMALE; HUMAN; HYPERPROLACTINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MICROADENOMA; MIDDLE AGED; OBESITY; PREVALENCE; PRIORITY JOURNAL; PROLACTINOMA; TREATMENT DURATION; BLOOD; DOSE RESPONSE; DRUG EFFECTS; METABOLIC DISEASES; METABOLISM; PITUITARY NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; CLINICAL EVALUATION; INSULIN SENSITIVITY; LIPID ANALYSIS; PREDICTOR VARIABLE; PROLACTIN BLOOD LEVEL;

ADIPOSITY; ADULT; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOLINES; FASTING; FEMALE; HUMANS; HYPERPROLACTINEMIA; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC DISEASES; METABOLIC SYNDROME X; PITUITARY NEOPLASMS; PREVALENCE; PROGNOSIS; PROLACTIN; PROLACTINOMA; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896493454     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000357810     Document Type: Article

References (88)

1. Knudtzon J, Johansen PW, Haug E, Gautvik K: Effects of hypersecretion of growth hormone and prolactin on plasma levels of gluca-gon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment. Life Sci 1986; 39:617-621.
2. Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ: Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol 1993; 264:E986-E992.
3. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA: Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 1998; 19:225-268.
4. Ben-Jonathan N, Hugo ER, Brandebourg TD, La Pensee CR: Focus on prolactin as a metabolic hormone. Trends Endocrinol Metab 2006; 17:110-116.
5. Baptista T, Lacruz A, de Mendoza S, Mendoza Guillen JM, Silvera R, Angeles F, Mendoza MT, Hernandez L: Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81-88.
6. Doknic M, Pekic S, Zarkovic M, Medic-Sto-janoska M, Dieguez C, Casanueva F, Popovic V: Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocrip-tine. Eur J Endocrinol 2002; 147:77-84.
7. Greenman Y, Tordjman K, Stern N: Increased body weight associated with prolactin-secret-ing pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocri-nol (Oxf) 1998; 48:547-553.
8. Colao A, Sarno A, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G: Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J En-docrinol 2003; 148:325-331.
9. Brandebourg T, Hugo E, Ben-Jonathan N: Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab 2007; 9:464-476.
10. Strader AD, Buntin JD: Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hy-perphagia. J Neuroendocrinol 2003; 15:1046-1053.
11. Bina KG, Cincotta AH: Dopaminergic agonists normalize elevated hypothalamic neuro-peptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71: 68-78.
12. Atmaca A, Bilgici B, Ecemis GC, Tuncel OK: Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premeno-pausal women with hyperprolactinemia. Endocrine 2013; 44:756-761.
13. Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM: Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 1998; 178: 1010-1015.
14. Butte NF, Hopkinson JM, Nicolson MA: Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab 1997; 82:585-589.
15. Balci H, Akgun-Dar K, Gazioglu N, Kapucu A, Bolayirli M, Oz B: The relationship between prolactin, leptin, nitric oxide, and cyto-kines in patients with hyperprolactinemia. Pituitary 2009; 12:170-176.
16. Augustine RA, Grattan DR: Induction of central leptin resistance in hyperphagic pseudo-pregnant rats by chronic prolactin infusion. Endocrinology 2008; 149:1049-1055.
17. Sauvé D, Woodside B: Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res 2000; 868: 306-314.
18. Wang GJ, Volkow ND, Logan J, Pappas NR, Wong CT, Zhu W, Netusil N, Fowler JS: Brain dopamine and obesity. Lancet 2001; 357:354-357.
19. Kok P, Roelfsema F, Frolich M, Meinders AE, Pijl H: Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004; 89:4445-4449.
20. Sorenson RL, Brelje TC: Adaptation of islets of Langerhans to pregnancy: β-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res 1997; 29: 301-307.
21. Weinhaus AJ, Stout LE, Bhagroo NV, Brelje TC, Sorenson RL: Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol 2007; 193:367-381.
22. Nagano M, Kelly PA: Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem 1994; 269:13337-13345.
23. Moldrup A, Petersen ED, Nielsen JH: Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells. Endocrinology 1993; 133:1165-1172.
24. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL: Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription-5 in pancreatic islets of Langerhans. Endocrinology 2004; 145:4162-4175.
25. Vasavada RC, Garcia-Ocana A, Zawalich WS, Sorenson RL, Dann P, Syed M, Ogren L, Tala-mantes F, Stewart AF: Targeted expression of placental lactogen in the β cells of transgenic mice results in β-cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem 2000; 275:15399-15406.
26. Landgraf R, Landraf-Leurs MM, Weissmann A, Horl R, von Werder K, Scriba PC: Prolac-tin: a diabetogenic hormone. Diabetologia 1977; 13:99-104.
27. Johnston DG, Alberti KG, Nattrass M, Burrin JM, Blesa-Malpica G, Hall K, Hall R: Hyper-insulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf) 1980; 13:361-368.
28. Schernthaner G, Prager R, Punzengruber C, Luger A: Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 1985; 28:138-142.
29. Tuzcu A, Yalaki S, Arikan S, Gokalp D, Bah-cec M, Tuzcu S: Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglyce-mic hyperinsulinemic clamp technique. Pituitary 2009; 12:330-333.
30. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G: The influences of hy-perprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 2006; 64:366-370.
31. Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S: Insulin sensitivity and hyperpro-lactinemia. J Endocrinol Invest 2003; 26:341-346.
32. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S: Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic premeno-pausal women. Eur J Endocrinol 2003; 149: 187-193.
33. Biller BM, Colao A, Petersenn S, Bonert VS, Boscaro M: Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord 2010; 10:10.
34. Gillam MP, Molitch ME, Lombardi G, Colao A: Advances in the treatment of prolactino-mas. Endocr Rev 2006; 27:485-534.
35. Cincotta A, Schiller B, Meier A: Bromocrip-tine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance and impaired glucose tolerance in the Syrian hamster, Mesoricetus auratus. Metabolism 1991; 40:639-644.
36. Cincotta A, MacEachern T, Meier A: Bro-mocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulin-emic state in Syrian hamsters. Am J Physiol 1993; 264:E285-E293.
37. Cincotta A, Meier A: Bromocriptine (Ergo-set) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996; 19:667-670.
38. Kamath V, Jones C, Yip J, Varasteh BB, Cin-cotta AH, Reaven GM, Chen YD: Effects of a quick-release form of bromocriptine (Er-goset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese non-diabetic hyperin-sulinemic women. Diabetes Care 1997; 20: 169 7-1701.
39. Cincotta AH, Meier AH, Taylor E, Hudson M: Bromocriptine (Ergoset) reduces body fat, hyperinsulinemia, and glucose intolerance in obese subjects (abstract). Diabetes 1995; 44(suppl 1):168A.
40. Galluzzi F, Salti R, Stagi S, La Cauza F, Chi-arelli F: Reversible weight gain and prolactin levels-long-term follow-up in childhood. J Pediatr Endocrinol Metab 2005; 18:921-924.
41. Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Ma-hankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, De Fronzo RA: Bro-mocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care 2000; 23: 1154-1161.
42. Holt RI, Barnett AH, Bailey CJ: Bromocripti-ne: old drug, new formulation and new indication. Diabetes Obes Metab 2010; 12:1048-1057.
43. Berinder K, Nystrom T, Hoybye C, Hall K, Hulting AL: Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 2011; 14:199-207.
44. Naliato EC, Violante AH, Gaccione M, Caldas D, Lamounier Filho A, Loureiro CR, Fontes R, Schrank Y, Costa FS, Colao A: Body fat in men with prolactinomas. J Endocrinol Invest 2008; 31:985-990.
45. Naliato EC, Violante AH, Caldas D, La-mounier Filho A, Loureiro CR, Fontes R, Schrank Y, Souza RG, Costa PL, Colao A: Body fat in non-obese women with prolacti-noma treated with dopamine agonists. Clin Endocrinol (Oxf) 2007; 67:845-852.
46. Dos Santos Silva CM, Barbosa FR, Lima GA, Warszawski L, Fontes R, Domingues RC, Gadelha MR: BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring) 2011; 19:800-805.
47. Korner J, Lo J, Freda PU, Wardlaw SL: Treatment with cabergoline is associated with weight loss in patients with hyperprolac-tinemia. Obes Res 2003; 11:311-312.
48. Ciresi A, Amato MC, Guarnotta V, Lo Castro F, Giordano C: Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin En-docrinol (Oxf) 2013, Epub ahead of print.
49. Amato MC, Giordano C, Galia M, Crisciman-na A, Vitabile S, Midiri M, Galluzzo A, Alka-MeSyStudy Group: Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33:920-922.
50. Ciresi A, Amato MC, Pizzolanti G, Giordano Galluzzo C: Visceral adiposity index is associated with insulin sensitivity and adipocyto-kine levels in newly diagnosed acromegalic patients. J Clin Endocrinol Metab 2012; 97: 2907-2915.
51. Amato MC, Verghi M, Galluzzo A, Giordano C: The oligomenorrhoic phenotypes of poly-cystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod 2011; 26:1486-1494.
52. WHO: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation. WHO Tech Rep Series 894. Geneva, WHO, 2000.
53. Chobanian AV, Bakris GL, Black HR, Cush-man WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. Hypertension 2003; 42:1206-1252.
54. World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation. Part. 1. Diagnosis and Classification of Diabetes Mellitus. Geneva, WHO, 1999.
55. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
56. Matthews DR, Hosker JP, Rudenski AS, Nay-lor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin in man. Diabetologia 1985; 28: 412-419.
57. 0, 120): comparison with other measures. Diabetes Res Clin Pract 2000; 47:177-184.
58. Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A: Results of a single-center observational 10-year survey study on recurrence of hyperpro-lactinemia after pregnancy and lactation. J Clin Endocrinol Metab 2013; 98:372-379.
59. Auriemma RS, Pivonello R, Perone Y, Grasso LF, Ferreri L, Simeoli C, Iacuaniello D, Gas-peri M, Colao AA: 2013 safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol 2013; 169:359-366.
60. Ben-Jonathan N, Hnasko R: Dopamine as a prolactin inhibitor. Endocr Rev 2001; 22:724-763.
61. Pelkonen R, Salmi J, Lamberg BA: Interrelationship between TSH and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis. Acta Endocrinol (Copenh) 1982; 100:184-188.
62. Heshmati HM, Turpin G, de Gennes JL: Chronic hyperprolactinemia and plasma lip-ids in women. Klin Wochenschr 1987; 65: 516-519.
63. Oravec S, Tomecková E, Oravec D, Klacanský T, Blasková O, Valach A: Decreased apolipo-protein levels in women with hyperprolac-tinemia related to increased estradiol level: effect of hepatic lesion? Endocrinol Exp 1985; 19:312-316.
64. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O: Blood coagulation, fibrinolysis and lipid profile in patients with prolactino-ma. Clin Endocrinol (Oxf) 2010; 73:502-507.
65. McAveney KM, Gimble JM, Yu-Lee L: Prolac-tin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology 1996; 137:5723-5726.
66. Symonds ME, Phillips ID, Anthony RV, Owens JA, McMillen IC: Prolactin receptor gene expression and foetal adipose tissue. J Neuro-endocrinol 1998; 10:885-890.
67. Gualillo O, Lago F, García M, Menéndez C, Señarís R, Casanueva FF, Diéguez C: Prolac-tin stimulates leptin secretion by rat white adipose tissue. Endocrinology 1999; 140:5149-5153.
68. Hugo ER, Borcherding DC, Gersin KS, Loftus J, Ben-Jonathan N: Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab 2008; 93: 4006-4012.
69. Borcherding DC, Hugo ER, Idelman G, De Silva A, Richtand NW, Loftus J, Ben-Jonathan N: Dopamine receptors in human adipocytes: expression and functions. PloS One 2011; 6:e25537.
70. Contreras F, Foullioux C, Pacheco B, Maroun C, Bolívar H, Lares M, Leal E, Cano R, Bermú-dez V, Velasco M: Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther 2008; 15:397-402.
71. Liang Y, Lubkin M, Sheng H, Scislowski PW, Cincotta AH: Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta 1998; 1405:1-13.
72. Balbach L, Wallaschofski H, Völzke H, Nauck M, Dörr M, Haring R: Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC Endocr Dis-ord 2013; 13:12.
73. Sorenson RL, Brelje TC, Roth C: Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy. Endocrinology 1993; 133:2227-2234.
74. Brelje TC, Scharp DW, Lacy PE, Ogren L, Ta-lamantes F, Robertson M, Friesen HG, Soren-son RL: Effect of homologous placental lacto-gens, prolactins, and growth hormones on islet β-cell division and insulin secretion in rat, mouse, and human islets: implication for pla-cental lactogen regulation of islet function during pregnancy. Endocrinology 1993; 132: 879-887.
75. Petryk A, Fleenor D, Driscoll P, Freemark M: Prolactin induction of insulin gene expression: the roles of glucose and glucose trans-porter-2. J Endocrinol 2000; 164:277-286.
76. Fleenor DE, Freemark M: Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of tran-scription-5. Endocrinology 2001; 142:2805-2810.
77. Kim SY, Sung YA, Ko KS, Cho BY, Lee HK, Koh CS, Min HK: Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women. Korean J Intern Med 1993; 8:8-14.
78. Pelkonen R, Nikkilä EA, Grahne B: Serum lip-ids, postheparin plasma lipase activities and glucose tolerance in patients with prolactino-ma. Clin Endocrinol (Oxf) 1982; 16:383-390.
79. Foss MC, Paula FJ, Paccola GM, Piccinato CE: Peripheral glucose metabolism in human hy-perprolactinaemia. Clin Endocrinol (Oxf) 1995; 43:721-726.
80. 2-like receptors are expressed in pancreatic β cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280: 36824-36832.
81. Ericson LE, Håkanson R, Lundquist I: Accumulation of dopamine in mouse pancreatic β-cells following injection of L-dopa. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 1977; 13:117-124.
82. Zern RT, Bird JL, Feldman JM: Effect of increased pancreatic islet norepinephrine, do-pamine and serotonin concentration on insulin secretion in the golden hamster. Diabeto-logia 1980; 18:341-346.
83. Rosati G, Maioli M, Aiello I, Farris A, Agnet-ti V: Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease. Eur Neurol 1976; 14:229-239.
84. Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G, Hofland LJ, Lamberts SW, Colao A: The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009; 94: 223-230.
85. Kok P, Roelfsema F, Frölich M, van Pelt J, Meinders AE, Pijl H: Short-term treatment with bromocriptine improves impaired circa-dian growth hormone secretion in obese pre-menopausal women. J Clin Endocrinol Metab 2008; 93:3455-3461.
86. Vitale G, Brugts MP, Ogliari G, Castaldi D, Fatti LM, Varewijck AJ, Lamberts SW, Monti D, Bucci L, Cevenini E, Cavagnini F, France-schi C, Hofland LJ, Mari D, Janssen J: Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians' offspring. Aging (Albany NY) 2012; 4:580-589.
87. Ayyad C, Andersen T: Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1:113-119.
88. Matsuzawa Y, Sugiyama S, Sugamura K, Sum-ida H, Kurokawa H, Fujisue K, Konishi M, Akiyama E, Suzuki H, Nakayama N, Yama-muro M, Iwashita S, Jinnouchi H, Kimura K, Umemura S, Ogawa H: Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients. Circ J 2013; 77:2807-2815.